Illinois jury delivers a staggering blow to Reckitt Benckiser Group Plc’s RBGLY and RBGPF Mead Johnson, ordering a $60 million settlement after the tragic loss of a premature infant to NEC (necrotizing enterocolitis), linked to their Enfamil baby formula.
Negligence in warning against NEC risks proven, marking the beginning of a legal avalanche with countless lawsuits in the queue against Mead Johnson and Abbott Laboratories Inc ABT for their infant formulas.
In defiance of the jury’s verdict, Reckitt stated, “We grieve with Ms. Watson, yet firmly refute the accountability placed on Mead Johnson and the subsequent compensatory decision. The scientific and medical community’s challenge of the plaintiff’s claims was evident through the trial, supported by a dozen neonatologists.”
Reportedly, over 400 NEC litigations are pending against Mead Johnson and Abbott, stationed in federal courts in Chicago and various state jurisdictions, mirroring Watson’s legal battle.
Bloomberg, echoing the jury’s conclusion, emphasized, “Mead Johnson must realize the magnified NEC hazard posed by its formula. The US’s initial verdict is but a precursor to impending judicial repercussions, should infant formula manufacturers evade culpability for their acts of deception.”
Separately, the litigation involving Abbott’s Sturgis, Michigan plant shutdown and baby formula recall due to contamination concerns distinguishes itself from the NEC disputes, causing formula shortages nationwide last year.
Market Watch: ABT stocks plummet by 4.59% to $113.40 in the latest update this Friday.
Image courtesy of Studio952 via Shutterstock
